(Q36223917)

12 August 2017

1 reference

title

Lipids, metabolic syndrome, and risk factors for future cardiovascular disease among HIV-infected patients (English)

1 reference

12 August 2017

1 reference

cardiovascular disease

1 reference

Obiamiwe C Umeh

1

1 reference

12 August 2017

Judith S Currier

series ordinal

2

1 reference

12 August 2017

language of work or name

1 reference

1 August 2005

1 reference

12 August 2017

published in

Current HIV/AIDS reports

1 reference

12 August 2017

volume

2

1 reference

12 August 2017

issue

3

1 reference

12 August 2017

page(s)

132-139

1 reference

Effect of protease inhibitors on apolipoprotein B levels and plasma lipid profile in HIV-1-infected patients on highly active antiretroviral therapy

12 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11904-005-0006-6

Impact of nevirapine on lipid metabolism

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11904-005-0006-6

Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection?

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11904-005-0006-6

Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome

21 January 2018

1 reference

12 December 2020

A Comparison of the Effects of Nevirapine and Nelfinavir on Metabolism and Body Habitus in Antiretroviral-Naive Human Immunodeficiency Virus-Infected Patients: A Randomized Controlled Study

1 reference

12 December 2020

Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment

1 reference

12 December 2020

Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey

1 reference

12 December 2020

Coronary heart disease in HIV-infected individuals

1 reference

12 December 2020

Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors.

1 reference

12 December 2020

Atazanavir--a once-daily HIV protease inhibitor that does not cause dyslipidemia in newly treated patients: results from two randomized clinical trials

1 reference

12 December 2020

HIV, metabolic syndrome X, inflammation, oxidative stress, and coronary heart disease risk : role of protease inhibitor exposure.

1 reference

12 December 2020

Incidence of hyperlipidaemia in a cohort of 212 HIV-infected patients receiving a protease inhibitor-based antiretroviral therapy

1 reference

12 December 2020

Metabolic syndrome among HIV-infected patients: prevalence, characteristics, and related factors

1 reference

12 December 2020

Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile

1 reference

12 December 2020

Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV.

1 reference

12 December 2020

Increased de novo hepatic lipogenesis in human immunodeficiency virus infection

1 reference

12 December 2020

Prevalence of coronary heart disease and carotid arterial thickening in patients with the metabolic syndrome (The ARIC Study).

1 reference

12 December 2020

Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey

1 reference

12 December 2020

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

12 December 2020

Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study

1 reference

12 December 2020

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 reference

12 December 2020

Metabolic syndrome: definition, pathophysiology, and mechanisms

1 reference

12 December 2020

Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.

1 reference

12 December 2020

The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study

1 reference

12 December 2020

Long-term efficacy and safety of protease inhibitor switching to nevirapine in HIV-infected patients with undetectable virus load

1 reference

12 December 2020

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

12 December 2020

Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities

1 reference

12 December 2020

Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1

1 reference

12 December 2020

Premature lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitors.

1 reference

12 December 2020

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

1 reference

12 December 2020

Coronary lesions in young HIV-positive subjects at necropsy

1 reference

12 December 2020

Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine

1 reference

12 December 2020

HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia

1 reference

12 December 2020

Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate

1 reference

12 December 2020

Managing cardiovascular risk in patients with HIV infection

1 reference

12 December 2020

The syndromes of insulin resistance and acanthosis nigricans. Insulin-receptor disorders in man.

1 reference

12 December 2020

Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047.

1 reference

12 December 2020

Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles?

1 reference

12 December 2020

Increased VLDL-apoB and IDL-apoB production rates in nonlipodystrophic HIV-infected patients on a protease inhibitor-containing regimen: a stable isotope kinetic study

1 reference

12 December 2020

Combination antiretroviral therapy and the risk of myocardial infarction

1 reference

12 December 2020

Protease inhibitors and cardiovascular outcomes in patients with HIV-1

1 reference

12 December 2020

Impact of HIV infection and HAART on serum lipids in men.

1 reference

12 December 2020

Cholesterol reduction yields clinical benefit: impact of statin trials

1 reference

12 December 2020

Update: mortality attributable to HIV infection among persons aged 25-44 years--United States, 1994.

1 reference

12 December 2020

Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial

1 reference

12 December 2020

Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM

1 reference

12 December 2020

Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway

1 reference

12 December 2020

Fuel selection in human skeletal muscle in insulin resistance: a reexamination

1 reference

12 December 2020

Guidelines for the Evaluation and Management of Dyslipidemia in Human Immunodeficiency Virus (HIV)-Infected Adults Receiving Antiretroviral Therapy: Recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the

1 reference

12 December 2020

10.1007/S11904-005-0006-6

Identifiers

DOI

1 reference

12 August 2017

1 reference